KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Ionis Pharmaceuticals (IONS) over the last 12 years, with Q3 2025 value amounting to $28.8 million.

  • Ionis Pharmaceuticals' Other Non-Current Liabilities fell 9465.06% to $28.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.8 million, marking a year-over-year decrease of 9465.06%. This contributed to the annual value of $51.9 million for FY2024, which is 8989.29% down from last year.
  • According to the latest figures from Q3 2025, Ionis Pharmaceuticals' Other Non-Current Liabilities is $28.8 million, which was down 9465.06% from $59.1 million recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Other Non-Current Liabilities peaked at $538.1 million during Q3 2024, and registered a low of $6.9 million during Q4 2021.
  • Moreover, its 4-year median value for Other Non-Current Liabilities was $507.6 million (2023), whereas its average is $320.1 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 495.46% in 2024, then crashed by 9465.06% in 2025.
  • Over the past 4 years, Ionis Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $6.9 million in 2021, then soared by 7296.14% to $513.7 million in 2023, then crashed by 89.89% to $51.9 million in 2024, then plummeted by 44.56% to $28.8 million in 2025.
  • Its last three reported values are $28.8 million in Q3 2025, $59.1 million for Q2 2025, and $55.7 million during Q1 2025.